“third-rock-ventures” Archives

in
Entry Author Date Location
Constellation Reboots With Eye On Immuno-Oncology, Hires New CEO 05/25/17 Boston
Bio Leaders Mourn Passing of Genzyme Exec, Orphan Drug Innovator Termeer 05/14/17 Boston
Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline 05/02/17 Boston
Frequency Nabs $32M, Will Push Hearing-Loss Drugs To Human Studies 04/11/17 Boston
Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today 04/06/17 Boston
To Infinity and Beyond: Julian Adams on Missteps and His New Job 04/03/17 Boston
Third Rock’s Tango Aims For Drugs That Turn Cancer Against Itself 03/30/17 Boston
Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO 02/23/17 Boston
Rhythm Raises $41M to Bankroll Late-Stage Push For Obesity Drug 02/16/17 Boston
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
Foundation, Roche Deepen Ties as Genentech Vet Steps in for CEO Pellini 01/06/17 Boston
Neon Therapeutics Garners $70,000,000 Series B Round 01/06/17 Boston
Frequency, Led by MIT’s Langer, Aims to Fight Hearing Loss With Drugs 01/05/17 Boston
Neon Therapeutics Hauls in $70M for Personalized Cancer Vaccines 01/05/17 Boston
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work 01/03/17 Boston
REVOLUTION Medicines Garners $25,000,000 Series A Funding 12/22/16 San Francisco
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More 12/16/16 National
Goldfinch Bio Obtains $55,000,000 Series A Round 12/15/16 Boston
Goldfinch Bio Aims $55M and Cancer Strategy at Genetic Kidney Disease 12/14/16 Boston
Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More 11/18/16 National
Magenta Therapeutics Lands $48,500,000 Series A Financing 11/17/16 Boston
Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants 11/16/16 Boston
Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More 11/04/16 National
Third Rock Gets $616M to Grow New Crop of Biotech Startups 10/31/16 Boston
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer 09/21/16 Boston
Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More 09/16/16 National
Relay Therapeutics Garners $57,000,000 Series A Funding Round 09/15/16 Boston
New Relay Therapeutics Aims Supercomputers, $57M At Protein Motion 09/14/16 Boston
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push 09/12/16 Boston
Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More 07/22/16 National
Page 1 of 16 next page »